JP2016515141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515141A5 JP2016515141A5 JP2016502876A JP2016502876A JP2016515141A5 JP 2016515141 A5 JP2016515141 A5 JP 2016515141A5 JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016515141 A5 JP2016515141 A5 JP 2016515141A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- biomarker
- treatment
- pharmaceutical composition
- absence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/072638 WO2014139131A1 (en) | 2013-03-14 | 2013-03-14 | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| CNPCT/CN2013/072638 | 2013-03-14 | ||
| PCT/US2014/028714 WO2014153018A1 (en) | 2013-03-14 | 2014-03-14 | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202804A Division JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515141A JP2016515141A (ja) | 2016-05-26 |
| JP2016515141A5 true JP2016515141A5 (https=) | 2017-04-06 |
| JP6675300B2 JP6675300B2 (ja) | 2020-04-01 |
Family
ID=51535817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502876A Expired - Fee Related JP6675300B2 (ja) | 2013-03-14 | 2014-03-14 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
| JP2019202804A Pending JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202804A Pending JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US10442862B2 (https=) |
| JP (2) | JP6675300B2 (https=) |
| WO (2) | WO2014139131A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| US10484156B2 (en) * | 2016-11-16 | 2019-11-19 | Qualcomm Incorporated | Search space associated with physical downlink control channel based on channel quality indicators |
| CN110520543A (zh) * | 2017-03-29 | 2019-11-29 | 中美冠科生物技术（太仓）有限公司 | 确定胃癌对西妥昔单抗敏感性的系统和方法 |
| EP3635373B1 (en) * | 2017-06-06 | 2025-07-30 | University of Maryland, College Park | Analysis of single cell mechanical phenotyping for metastatic detection |
| CN107582993A (zh) * | 2017-11-10 | 2018-01-16 | 兰志英 | 一种治疗胃癌的药物及其制备方法 |
| JP7493237B2 (ja) * | 2018-11-14 | 2024-05-31 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
| CN113045661B (zh) * | 2021-04-07 | 2022-06-21 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537631T3 (es) | 2004-05-27 | 2015-06-10 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
| US20090214541A1 (en) * | 2006-01-04 | 2009-08-27 | L'instut National De La Sante Et De La Recherche Medicale | Combination Therapy Using Anti-EGFR and Anti-HER2 Antibodies |
| US8329421B2 (en) * | 2007-07-13 | 2012-12-11 | Ventana Medical Systems, Inc. | Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein |
| WO2010028288A2 (en) * | 2008-09-05 | 2010-03-11 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| WO2012157647A1 (ja) * | 2011-05-16 | 2012-11-22 | 大鵬薬品工業株式会社 | 胃癌患者に対するテガフール・ギメラシル・オテラシルカリウム配合剤及びｅｇｆｒ阻害剤からなる化学療法の選択方法 |
| WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
-
2013
- 2013-03-14 WO PCT/CN2013/072638 patent/WO2014139131A1/en not_active Ceased
-
2014
- 2014-03-14 US US14/775,117 patent/US10442862B2/en active Active
- 2014-03-14 WO PCT/US2014/028714 patent/WO2014153018A1/en not_active Ceased
- 2014-03-14 JP JP2016502876A patent/JP6675300B2/ja not_active Expired - Fee Related
-
2019
- 2019-11-08 JP JP2019202804A patent/JP2020040959A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ajani et al. | Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology | |
| Bell et al. | Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations | |
| Pestana et al. | Histology-agnostic drug development—considering issues beyond the tissue | |
| De Jesus-Acosta et al. | Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma | |
| Carlson et al. | NCCN Task Force Report: adjuvant therapy for breast cancer | |
| Wülfing et al. | A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma | |
| Locati et al. | A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact | |
| Prat et al. | Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay | |
| Iveson et al. | Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study | |
| Fuchs et al. | Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab | |
| Stintzing et al. | Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group | |
| JP2016515141A5 (https=) | ||
| De Mattos-Arruda et al. | Translating neoadjuvant therapy into survival benefits: one size does not fit all | |
| Muller et al. | Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma | |
| Wills et al. | Role of liquid biopsies in colorectal cancer | |
| Souche et al. | First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma | |
| Wang et al. | CC motif chemokine ligand 5 (CCL5) levels in gastric cancer patient sera predict occult peritoneal metastasis and a poorer prognosis | |
| Fleischmann et al. | ACO/ARO/AIO-21-Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group | |
| Jin et al. | Differential response to EGFR-and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases | |
| Robb et al. | Predicting the response to chemotherapy in gastric adenocarcinoma: who benefits from neoadjuvant chemotherapy? | |
| Pandey et al. | Personalized treatment approach for HER2-positive metastatic breast cancer | |
| Petrillo et al. | Biomarkers for precision treatment in gastric cancer | |
| Shuster et al. | Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer | |
| JP7298827B2 (ja) | 抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を予測する方法、がんの悪性度を評価する方法、及び抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を上昇させる方法 | |
| Akdogan et al. | The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer |